Biotech investor plans IPO in LondonBritish life science investor Arix Biosciences is planning an IPO at London Stock Exchange. The London-based investor aims to raise £100m (€116m) to reinvest in innovations in medical science. more ➔
Prize awarded to innovative productsIn early February, at the 20th edition of the Pharmapack Europe event, outstanding products were honoured with the Pharmapack Award. Organiser UBM EMEA also introduced a new Pharmapack Start-up Hub. more ➔
Molecule prevents oedema French researchers have identified a regulator which controls blood vessel permeability. Their findings open up the possibility to develop drugs preventing oedema that occur in large indications such … more ➔
Fighting AMR efficientlyMajor European stakeholders have released statements on how to fight antimicrobial resistance more effectively. Regulatory agencies such as EFSA and EMA call for locally adapted combination strategies … more ➔
uniQure gets FDA breakthrough status for A...Dutch gene therapy specialist uniQure Biopharma BV will be able to rapidly develop its haemophilia B gene therapy AMT-060. Based on data of a Phase I/II safety study, the FDA granted breakthrough therapy … more ➔
IBAM completes US$690m dealBelgian-headquartered IBA Molecular has completed the acquisition of British Mallinckrodt’s nuclear imaging business summing up to approximately US$690m. more ➔
€500m to push gene therapyGerman Christian democrats have started the election year underpinning their intention to pump money into life science research and into its translation into products. more ➔
Johnson & Johnson to buy Actelion for...Following a month-long take-over poker, J&J’s and Actelion’s boards have agreed to support an all-cash tender offer from J&J in which shareholders are set to receive US$280.08 per share and one … more ➔
HCC: resminostat boosts overall survivalGerman 4SC AG’s epigenetic cancer drug resminostat is back. What seemed to be a flop after Phase II failure has being transformed into a success story of personalised medicine. By accurate data analysis … more ➔
GM mosquitoes to be released in India Oxford-based Intrexion-subsidiary Oxitec plans to release male GM mosquitoes that produce nonviable offspring in India, in order to limit the spread of dengue and chikungunya fevers transmitted by Aedes … more ➔
